Several cancer chemotherapies cause nausea and vomiting, which can be dose-limiting. Musk shrews are used as preclinical models for chemotherapy-induced emesis and for antiemetic effectiveness. Unlike rats and mice, shrews possess a vomiting reflex and demonstrate an emetic profile similar to humans, including acute and delayed phases. As with most animals, dosing of shrews is based on body weight, while translation of such doses to clinically equivalent exposure requires doses based on body surface area. In the current study body surface area in musk shrews was directly assessed to determine the Meeh constant (K m ) conversion factor (female ¼ 9.97, male ¼ 9.10), allowing estimation of body surface area based on body weight. These parameters can be used to determine dosing strategies for shrew studies that model human drug exposures, particularly for investigating the emetic liability of cancer chemotherapeutic agents.
07:00 h), and fed a mixture of 75% Purina Cat Chow Complete Formula and 25% Complete Gro-Fur mink food (Milk Specialties Co, New Holstein, WI, USA), with free access to food and water. Experiments were approved by the University of Pittsburgh's Institutional Animal Care and Use Committee, and the animal care and use program is approved by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).
Shrews were euthanized at the end of other, primary, studies using carbon dioxide (rising) or an intracardiac injection of Beuthanasia-D (0.2 mL ¼ 78 mg sodium pentobarbital; Henry Schein, Melville, NY, USA), under general anesthesia (urethane 1 g/kg intraperitoneally). 5 Euthanization was confirmed by cervical dislocation. For dissection, a medial incision was made on the ventral plane from the tip of the lower jaw to the end of the tail. The skin was removed from the muscle, except for the area surrounding the paws, which was left in place. The ears were removed from the pelt and these tissues were laid flat, along with a metric ruler, for imaging with a digital camera ( Figure 1b ).
Using ImageJ software (National Institutes of Health, Bethesda, MD, USA), traces were made of the skin (Figure 1c ). The total area was computed (converting the scale from pixels to centimeters) by subtracting the ear holes and adding the ears and paws, doubled to account for two surfaces (Figure 1c ).
Data for male and female shrews were analyzed separately, and for each animal computed K m ¼ BSA/ (BW 2/3 ). 9 The distribution of the K m values were examined with histograms, and determined to be normally distributed based on the Shapiro-Wilk's test, so the mean was calculated and used as an estimate of K m , including a 95% confidence interval (CI). The prediction error, defined as the observed BSA minus the calculated BSA, was calculated for each animal and plotted against BW to determine if the prediction error had a trend related to BW. However, this trend was not observed for either sex, indicating that the data fitted the formula well. Also, the root mean square prediction error (RMSE) was calculated for each datum, along with its 95% CI. 10 Two-sided t-tests were used to compare males and females.
Females had a lower BW compared with males (mean ¼ 40.47, SD ¼ 3.62, median ¼ 40.00, range ¼ 36.60-50.90; compared with mean ¼ 68.91, SD ¼ 8.03, median ¼ 68.3 g, and range ¼ 50.90-88.20, P < 0.0001). Similarly, BSA was less in females (mean ¼ 117.5, SD ¼ 9.6, median ¼ 118.7, range ¼ 96.79-134.7; compared with mean ¼ 152.8, SD ¼ 14.3, median ¼ 150.6, and range ¼ 116.9-195.5 cm 2 , P < 0.0001). See scatterplots for BSA by BW ( Figure 2a ) and age ( Figure 2b ). Females had an average K m value of 9.97 (SD ¼ 0.68, median ¼ 10.12, 95% CI of 9.67 and 10.27; RMSE ¼ 7.79 with 95% CI of 3.32 and 10.51) and males a value of 9.10 (SD ¼ 0.66, median ¼ 9.17, 95% CI of 8.81 and 9.39; RMSE ¼ 11.21 with 95% CI of 8.05 and 13.66), respectively. The K m was significantly different between the sexes (P < 0.0001).
Our data indicate that K m can be used to estimate BSA. Shrew BW relative to BSA is in close agreement with measures from other mammals (Figure 2c ). Using shrew K m values, chemotherapeutic drug dosages were estimated from prior studies. Typical doses of the chemotherapeutic agent cisplatin used in shrew studies of emesis were 10, 20, and 30 mg/kg BW, 4,11-14 which convert to 100, 199, and 299 mg/m 2 for females and 91, 182, and 273 for males (mg/kg value Â K m ). A cisplatin dosage of approximately >70 mg/m 2 is highly emetogenic in humans, 15 but the equivalent dose in musk shrews (female, 7.0; male, 7.7 mg/kg) does not produce emesis. In our previous shrew pharmacokinetic study, ultrafilterable platinum clearance normalized to BSA utilizing K m is 341 mL/min/m 2 , which is similar to the value reported in humans of 397 mL/min/m 2 (assuming a 70 kg, 1.73 m human), 16, 17 which suggests that there may be a susceptibility difference between humans and shrews. 
Resumen
Varias quimioterapias contra el cáncer producen náuseas y vómitos, lo cual puede limitar la dosis. Las musarañas caseras son un modelo preclínico para la emesis inducida por la quimioterapia y para una efectividad antiemética. A diferencia de las ratas, las musarañas poseen un reflejo de vómito y muestran un perfil emético similar al de los humanos, incluidas las fases agudas y retrasadas. Como con la mayoría de animales, la dosificación de las musarañas se basa en el peso corporal, mientras que la traslación de dichas dosis a una exposición clínicamente equivalente requiere una dosis basada en el área de la superficie corporal. En el estudio actual, evaluamos directamente el área de superficie corporal en musarañas caseras para determinar el factor de conversión Km (hembras ¼ 9.97, machos ¼ 9.10), permitiendo una estimación del área de superficie corporal basada en el peso corporal. Estos parámetros pueden utilizarse para determinar estrategias de dosificación para estudios con musarañas que reflejan exposiciones a antibióticos en humanos, en particular para investigar la carga emética de los agentes quimioterapéuticos para el tratamiento del cáncer.
